Daily oral PrEP with FTC/TAF is noninferior to FTC/TDF in preventing HIV infection in cis-MSM and transgender women at high risk for HIV acquisition.
Among individuals recently diagnosed with HIV, those who received PrEP prior to diagnosis were more likely to harbor emtricitabine resistance mutations and to be diagnosed with acute HIV infection vs never-users of PrEP.
Switch to long-acting dual therapy regimen maintains virologic suppression at Week 48.
Higher patient-reported satisfaction with monthly injectable dual regimen compared with daily oral tablets.
In this post-hoc analysis of HIV-infected adults previously failing first-line therapy with NNRTI + 2 NRTIs, HIV-1 RNA < 50 copies/mL was achieved in 82% of DTG recipients with baseline M184V/I and second-line use of 3TC or FTC.
Although the overall death rate decreased by 13% from 2011-2015 among HIV-infected individuals, a 43% increase in opioid overdose deaths among the US HIV population was reported.
Post hoc analysis finds no evidence of association between cabotegravir use and weight gain.
First large randomized study of raltegravir vs efavirenz in pregnant women finds improved virologic suppression at delivery in women receiving raltegravir, particularly when initiating ART after 28 weeks of gestation.
In pregnant women with HIV infection who initiated third trimester ART, HIV-1 RNA < 50 copies/mL at delivery achieved in 74% with DTG-based therapy vs 43% with EFV-based therapy.
No drug-related serious adverse events and PK exposures comparable to adults with single-tablet regimen BIC/FTC/TAF in patients 6 to < 18 years of age.